OmniAb (OABI) Scheduled to Post Earnings on Tuesday

OmniAb (NASDAQ:OABI) is scheduled to be releasing its earnings data after the market closes on Tuesday, November 12th. Analysts expect OmniAb to post earnings of ($0.14) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

OmniAb (NASDAQ:OABI) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. OmniAb had a negative net margin of 287.29% and a negative return on equity of 20.21%. The business had revenue of $7.61 million for the quarter, compared to analysts’ expectations of $6.52 million. During the same period in the previous year, the business earned ($0.15) earnings per share. On average, analysts expect OmniAb to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OmniAb Stock Down 0.2 %

Shares of NASDAQ OABI opened at $4.52 on Friday. The firm’s 50-day simple moving average is $4.17 and its 200 day simple moving average is $4.28. The stock has a market cap of $534.08 million, a P/E ratio of -7.29 and a beta of -0.12. OmniAb has a fifty-two week low of $3.56 and a fifty-two week high of $6.72.

Analyst Upgrades and Downgrades

OABI has been the topic of a number of research analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 target price on shares of OmniAb in a report on Friday, August 16th. Benchmark reaffirmed a “buy” rating and set a $8.00 target price on shares of OmniAb in a report on Monday, August 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of OmniAb in a report on Monday, August 12th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.